Monash University, based in Melbourne, Australia, is renowned for its global impact in research, quality teaching, and innovative leaps, has previously scribed its name in numerous breakthroughs in medical science. The Australian Regenerative Medicine Institute (ARMI) at Monash has been a cornerstone, exploring the regenerative process’s underlying mechanisms to contrive solutions for diseases, injuries, and genetic conditions. ARMI, in collaboration with Monash’s commercialization and MNHS business development teams, has brought forth ventures that echo their commitment to transformative medical solutions, such as their recent partnership with Orio Therapeutics.
Co-founded by Dr. Ziad Julier and Associate Professor Mikaël Martino of ARMI, Orio Therapeutics has developed a groundbreaking drug delivery technology that modifies therapeutic proteins to augment their delivery via controlled, slow release, and consistent dosing. This advancement circumvents the shortcomings of current protein-based therapeutics in regenerative medicine, which are often plagued by sub-optimal delivery systems requiring large, frequent doses and accompanying high costs and potential side effects.
“The partnership represents an exciting opportunity to bring our revolutionary drug delivery technology to the forefront of regenerative medicine. With the support of Monash, we aim to revolutionize patient care and move the field forward,” commented Dr. Julier, reflecting palpable enthusiasm for the collaboration and the prospective impact of their technology.
This endeavor promises a transformative impact on the regenerative medicine realm, offering a novel approach to tissue regeneration and repair while simultaneously addressing previously unmet medical needs and enhancing patient outcomes. The first candidate from Orio Therapeutics encapsulates this ambition: a cardioprotective drug aimed at meticulous care for post-heart attack patients.
A revolutionary shift in medicine
Dr. Julier and Associate Professor Martino will spearhead the commercialization process, engaging with potential investors and international industrial partners. Headquartered at the BioArk technology site in Monthey (canton of Valais), Orio Therapeutics seeks to navigate through the global biotech landscape, infusing their innovative approach with viable commercial strategies.
With its eyes set on continual development and evolution, Orio Therapeutics is currently seeking of seed capital for the expansion of its team and pre-clinical studies.
